2026.09.02Vol.9 No.19 AI 【From "AI-integrated PV" to "AI-native PV" — What Should PV Organizations Start in FY2027?】
2026.08.30Vol.9 No.18 AI Redesigning the PV Organization in the Age of AI — Will Pharmacovigilance Professionals Still Be Needed?
2026.08.15Vol.9 No.16 AI How should an MAH read an AI-PV Case Study? — Reflections on the BMS / ArisGlobal NavaX case —
2026.08.14Vol.9 No.15 AI 【Preview + Episode#1 - #6 New Series How Should Humans Be Involved with AI? — Rethinking Human Oversight】 AI is rapidly becoming part of everyday business and society. <▶ Please expand it.>
2026.08.11Vol.9 No.14 AI HPC New Series AI-PV| Chapter 4: "If an audit asks you to explain AI, what should you show?"
2026.08.11Vol.9 No.13 AI [AI-PV business] What is the difference between HITL and HOTL? Advantages/disadvantages and design methods for pharmacovigilance
2026.07.26Vol.9 No.12 AI HPC NEW Series Trailer + 6 Episodes: AI-PV: Where Do We Actually Start? 6-Questions PV Leaders and Teams Need to Answer
2026.07.13Vol.9 No.9 AI Introduction to CIOMS AI in PV 2025 Preprint Japanese version. CIOMS AI-PV 2025 [CIOMS AI-PV 2025: A Translator's Guide to Principles & Good Practices for AI in Pharmacovigilance
2026.05.25Vol.9 No.6 AI HiroPharmaConsulting, Starsphere to Collaborate on POC/FS Support for AI-PV. Combining Knowledge from PV, Clinical, GxP/CSV, and DX to Support Life Science Companies in Considering AI Utilization
2026.05.23Vol.9 No.5 AI EU Draft Guidelines on High-risk AI Classification: Practical Implications for PV and AI-PV
